Assembly Looks To Quickly Move Past ABI-H2158 Discontinuation

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company’s triple-combination studies with vebicorvir and next-generation core inhibitor programs may hold more promise in hepatitis B.

liver
• Source: Shutterstock

Although Assembly Biosciences, Inc.’s decision to stop development of its Phase II hepatitis B virus (HBV) drug ABI-H2158 is a near-term black eye for the company, the firm still has two triple-combination studies with its lead core inhibitor, vebicorvir, up its sleeve as well as additional next-generation core inhibitors. And those drugs offer significantly greater chances of commercial success, the company says.

South San Francisco, CA-based Assembly said on 1 September that it would discontinue development of ABI-H2158 after four patients showed...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D